SAB Biotherapeutics, Inc. (SABS)

NASDAQ: SABS · Real-Time Price · USD

3.810

+0.190 (5.25%)

At close: Aug 25, 2026, 4:00 PM EDT

3.880

+0.070 (1.84%)

After-hours: Aug 25, 2026, 4:51 PM EDT

SAB Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	8.27	10.5	8.9	56.57	15.05	33.21
Short-Term Investments	94.37	86.09	11.86	-	-	-
Cash & Short-Term Investments	102.63	96.59	20.76	56.57	15.05	33.21
Cash Growth	1696.29%	365.27%	-63.30%	275.93%	-54.69%	163.33%
Accounts Receivable	-	-	-	-	5.56	8.01
Other Receivables	1.84	0.95	0.05	-	-	-
Receivables	1.84	0.95	0.05	-	5.56	8.01
Prepaid Expenses	3.46	3.51	2.98	2.34	1.49	2.64
Restricted Cash	-	-	-	-	-	6.34
Total Current Assets	107.94	101.05	23.79	58.91	22.1	50.19
Property, Plant & Equipment	19.58	19.4	19.92	24.68	28.34	30.95
Long-Term Investments	105.35	46.89	-	-	-	-
Long-Term Deferred Charges	-	0.15	0.26	-	-	-
Other Long-Term Assets	5.34	5.31	0.22	0.35	0.47	-
Total Assets	238.21	172.81	44.2	83.94	50.9	81.14

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	3.86	3.15	1.69	0.95	3.68	4.46
Accrued Expenses	7.21	6.58	5.47	6.69	9.83	11.91
Current Portion of Long-Term Debt	-	-	0.28	1.05	0.77	1.8
Current Portion of Leases	0.64	0.95	0.54	0.8	0.62	1.3
Current Unearned Revenue	-	-	-	1.32	-	0.1
Other Current Liabilities	-	-	-	-	0.09	6.89
Total Current Liabilities	11.71	10.68	7.98	10.81	14.99	26.46
Long-Term Debt	-	-	-	-	0.54	-
Long-Term Leases	4.49	5	3.86	4.05	3.99	5.42
Other Long-Term Liabilities	7.23	5.64	6.39	11.77	0.32	10.72
Total Liabilities	23.43	21.32	18.23	26.64	19.85	42.59

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.01	0	0	0	0	0
Additional Paid-In Capital	373.48	267.72	155.79	152.86	84.45	67.67
Retained Earnings	-152.26	-110.9	-124.17	-90.06	-47.87	-29.13
Treasury Stock	-5.52	-5.52	-5.52	-5.52	-5.52	-
Comprehensive Income & Other	-0.93	0.19	-0.14	0.03	-	-
Total Common Equity	214.79	151.49	25.97	57.3	31.06	38.55
Shareholders' Equity	214.79	151.49	25.97	57.3	31.06	38.55
Total Liabilities & Equity	238.21	172.81	44.2	83.94	50.9	81.14

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	5.13	5.95	4.67	5.91	5.93	8.52
Net Cash (Debt)	97.5	90.64	16.09	50.66	9.12	24.69
Net Cash Growth	-	463.28%	-68.23%	455.59%	-63.07%	450.61%
Net Cash Per Share	2.03	1.48	1.74	9.17	2.09	9.03
Filing Date Shares Outstanding	90.99	50.95	9.29	9.23	5.04	4.3
Total Common Shares Outstanding	83.49	47.61	9.29	9.23	5.04	4.35
Working Capital	96.23	90.37	15.81	48.09	7.1	23.74
Book Value Per Share	2.57	3.18	2.80	6.21	6.16	8.86
Tangible Book Value	214.79	151.49	25.97	57.3	31.06	38.55
Tangible Book Value Per Share	2.57	3.18	2.80	6.21	6.16	8.86
Machinery	16	14.6	14.52	11.99	11.57	8.87
Construction In Progress	0.41	0.76	-	-	0.31	4.61
Leasehold Improvements	16	15.47	15.42	17.65	9.3	5.7

SEC Filings: 10-K · 10-Q